Introduction {#s1}
============

Lewy body disorders, such as Parkinson's disease (PD), PD dementia (PDD), and dementia with Lewy bodies (DLB), are neurodegenerative diseases characterized by accumulation of Lewy bodies in brain cells ([@CIT0024]). Cognitive impairment is an important feature of all Lewy body disorders ([@CIT0018]).

A recent meta-analysis showed that cholinesterase inhibitors (ChEIs) (donepezil, galantamine, and rivastigmine) were superior to placebo in improving cognitive function in patients with AD ([@CIT0038]). In addition, ChEIs have recently been tested for the treatment of Lewy body disorders based on studies reporting cholinergic system dysfunction in these patients ([@CIT0005]; [@CIT0040]; [@CIT0004]). The efficacy of ChEIs in managing patients with DLB, PDD, and cognitive impairment in PD (CIPD) was assessed in a Cochrane meta-analysis of 6 randomized controlled trials (RCTs) including 1263 patients ([@CIT0036]). This meta-analysis revealed that pooled ChEIs were superior to placebo in improving cognitive function in patients with DLB, PDD, and CIPD (standardized mean difference \[SMD\] = −0.34, 95% confidence interval \[CI\] = −0.46 to −0.23, *P* \< .00001\]. [@CIT0041] conducted a meta-analysis of 7 RCTs (1403 patients) evaluating ChEIs (donepezil and rivastigmine) and memantine for DLB, PDD, and CIPD; results revealed that donepezil and rivastigmine were superior to placebo in improving cognitive function, as assessed by Mini-Mental State Examination (MMSE) ([@CIT0016]) in patients with DLB, PDD, and CIPD (5-mg donepezil: weighted mean difference \[WMD\] = −2.57, 95% CI = −4.23 to −0.90, *P* = .003, 3 RCTs, n = 440; 10mg donepezil: WMD = −1.31, 95% CI = −2.53 to −0.09, *P* = .04, 4 RCTs, n = 450; and 12-mg rivastigmine: WMD = −1.04, 95% CI = −1.65 to −0.43, *P* = .0009, 2 RCTs, n = 621\].

As PD is a Lewy body disorder, we performed a meta-analysis of ChEI safety and efficacy for treating patients with Lewy body disorders, including DLB, PDD, CIPD, and PD. This analysis pooled the results of 17 RCTs (involving 1798 patients) using the same methodology as that used in our previous meta-analysis ([@CIT0027]).

Methods {#s2}
=======

This meta-analysis was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines ([@CIT0030]). We systematically reviewed the literature using the PICO strategy (patients: Lewy body disorders; intervention: ChEIs, including donepezil, galantamine, and rivastigmine; comparator: placebo or usual care; outcomes: cognitive function \[primary\], behavioral disturbances \[primary\], motor function \[primary\], global function, activities of daily living, discontinuation rate, and individual adverse effects).

Inclusion Criteria, Search Strategy, Data Extraction, and Outcome Measures {#s3}
--------------------------------------------------------------------------

We included only RCTs of ChEIs for patients with Lewy body disorders. Open-label, nonplacebo-controlled (ie, usual care), and crossover studies were included for increasing the sample size. To identify relevant studies, we searched PubMed, Cochrane Library databases, EMBASE, CINAHL, and PsycINFO citations. There were no language restrictions, and we considered all studies published up to July 14, 2015. We used the following key words: "cholinesterase inhibitor," "donepezil," "galantamine," "rivastigmine," "Lewy," "Parkinson disease," or "Parkinson's disease." Additional eligible studies were sought by searching the reference lists of the primary articles and relevant reviews.

Two authors (S.M. and T.K.) scrutinized the patient inclusion and exclusion criteria for the identified studies. When data required for the meta-analysis were missing, the first and/or corresponding authors were contacted for additional information, including endpoint scores. Three authors (S.M., T.K., and I.Y.) independently extracted, assessed, and entered the data into Review Manager (Version 5.3 for Windows, Cochrane Collaboration, <http://ims.cochrane.org/revman>). Discrepancies in different coding forms were resolved by discussions between authors (S.M. and T.K.)

Data Synthesis and Statistical Analysis {#s4}
---------------------------------------

Each outcome measure reported in this study was used in at least 3 of the 17 included studies. The primary outcome measures of efficacy were cognitive function, behavioral disturbances, and motor function. Cognitive function was assessed by MMSE, modified MMSE ([@CIT0039]), or Montreal Cognitive Assessment ([@CIT0009]). Behavioral disturbances were assessed by Neuropsychiatric Inventory ([@CIT0008]) and Brief Psychiatric Rating Scale ([@CIT0034]). Motor function was assessed by Unified Parkinson's Disease Rating Scale-motor (UPDRS-motor) ([@CIT0015]). Secondary outcome measures included ADL, global function, all-cause discontinuation, discontinuation due to adverse events, and incidence of individual adverse events. ADL was assessed by Alzheimer's Disease Co-operative Study-Activities of Daily Living Inventory ([@CIT0017]), Unified Parkinson's Disease Rating Scale-Activities of Daily Living ([@CIT0015]), and Zarit Caregiver Burden Interview ([@CIT0042]). Global function was assessed by Clinician's Interview-Based Impression of Change plus Caregiver Input ([@CIT0033]) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change ([@CIT0037]).

We based our analyses on intent-to-treat (ITT) or modified ITT data (ie, at least 1 dose or at least 1 follow-up assessment). However, we analyzed the complete set of data for ensuring that the maximum possible information was included ([@CIT0032]; [@CIT0025]).

For combining studies, we used the random effects model of [@CIT0010]. This model is more conservative than the fixed effects model and provides a wider CI. For continuous data, we calculated Hedges' g SMD effect sizes and used the cut-off values for small, medium, and large effect sizes (0.2, 0.5, and 0.8, respectively) set by [@CIT0007]. If SD was not reported, it was calculated from the 95% CI ([@CIT0020]). Furthermore, for dichotomous data, the risk ratio (RR) was estimated along with 95% CIs. When the random effects model revealed significant differences between groups, the number needed to harm (NNH) was calculated from the risk difference as NNH = 1/ risk difference. We explored study heterogeneity using the *I* ^*2*^ statistic, with values of ≥50% regarded as considerable heterogeneity ([@CIT0021]). In cases with *I* ^*2*^ ≥ 50% for the primary outcome measures, we conducted sensitivity analyses for determining the reasons for heterogeneity. We examined the following confounding factors: blinding (double-blind or not), placebo-controlled or non-placebo--controlled trial, diagnosis (DLB, PDD + CIPD, or PD), trial duration (\>12 weeks or ≤12 weeks, as 12 weeks was the median of the study duration for all included trials), type of ChEI (donepezil, galantamine, or rivastigmine), sample size (\>28 per group or ≤28 as 28 was the median number of participants per group), sponsorship (industry sponsored or not), and quality of the trial design (high quality trial or "other," where high quality is defined as double-blind, parallel, and placebo-controlled as well as ITT or modified ITT analysis). Funnel plots were visually inspected for assessing the possibility of publication bias. We also assessed the methodological qualities of the articles included on the basis of the Cochrane risk of bias criteria (Cochrane Collaboration; <http://www.cochrane.org/>).

Results {#s5}
=======

Characteristics of the Included Studies {#s6}
---------------------------------------

The search yielded a total of 946 references, of which 550 were duplicates ([Figure 1](#F1){ref-type="fig"}). We excluded 360 references for not meeting our criteria after reviewing the title and abstract, and a further 19 were excluded after full-text reviews because they provided duplicate studies (n = 12), review articles (n = 5), or non-RCTs (n = 2). Seventeen RCTs were finally included for testing ChEIs for Lewy body disorders.

![The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flow diagram.](ijnppy_pyv086_f0001){#F1}

The 17 RCTs included 1798 patients ([@CIT0028]; [@CIT0001]; [@CIT0002]; [@CIT0014]; [@CIT0023]; [@CIT0032]; [@CIT0035]; [@CIT0029]; [@CIT0025]; [@CIT0019]; [@CIT0006]; [@CIT0012]; [@CIT0013]; [@CIT0031]; [@CIT0011]; [@CIT0022]; [@CIT0026]). The studies included 4 on ChEIs for DLB ([@CIT0028]; [@CIT0002]; [@CIT0031]; [@CIT0022]), 7 on ChEIs for PDD and CIPD ([@CIT0001]; [@CIT0014]; [@CIT0023]; [@CIT0035]; [@CIT0025]; [@CIT0013]; [@CIT0026]), and 6 on ChEIs for PD ([@CIT0032]; [@CIT0029]; [@CIT0019]; [@CIT0006]; [@CIT0012]; [@CIT0011]). Ten studies were double-blind, parallel, and placebo-controlled ([@CIT0028]; [@CIT0014]; [@CIT0023]; [@CIT0029]; [@CIT0019]; [@CIT0012]; [@CIT0013]; [@CIT0031]; [@CIT0011]; [@CIT0022]), 1 was open-label, parallel, and non-placebo--controlled ([@CIT0025]), 5 were double-blind, placebo-controlled, and single-crossover ([@CIT0001]; [@CIT0032]; [@CIT0035]; [@CIT0006]; [@CIT0026]), and 1 was double-blind, placebo-controlled, double-crossover ([@CIT0002]). The mean study duration was 13 weeks (4--26 weeks). Further, 7 to 550 patients were included in each study. The mean age of the entire study population was 72 years. Twelve of 17 studies were sponsored by pharmaceutical companies. Eight studies were conducted in the United States; 2 in Japan; 1 each in France, Italy, Norway, and Russia; and 3 in multiple countries. The characteristics of the trials included are summarized in [Table 1](#T1){ref-type="table"}. We evaluated the methodological quality of all studies using the Cochrane risk of bias criteria ([Figure 2](#F2){ref-type="fig"}). Eight studies ([@CIT0002]; [@CIT0023]; [@CIT0032]; [@CIT0035]; [@CIT0029]; [@CIT0025]; [@CIT0006]; [@CIT0012]) did not mention the method of randomization. Furthermore, 8 studies ([@CIT0002]; [@CIT0032]; [@CIT0029]; [@CIT0025]; [@CIT0019]; [@CIT0006]; [@CIT0012]; [@CIT0013]) did not mention the method of allocation concealment. One study was an open trial ([@CIT0025]), and 2 ([@CIT0032]; [@CIT0025]) used a complete analysis. One study ([@CIT0002]) did not report detailed information regarding method of statistical analysis; therefore, we did not include any data in the meta-analysis.

###### 

Characteristics of Included Trials

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                                                                                                **Total n**   **Patients**                                                                                                                                                                           **Diagnosis**                                                **Duration**                 **Age (mean ± SD**)    **Male (%**)       **Race (%**)   **Drug**    **n**   **Dose (dose mg/day**)   **Outcomes**
  ------------------------------------------------------------------------------------------------------------------------ ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------- ---------------------- ------------------ -------------- ----------- ------- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aarsland 2002\                                                                                                           14            Patients: CIPD\                                                                                                                                                                        Definite or probable PD: published criteria (Larsen 1994)\   10 weeks\                    71±3.9                 92                 NR             DON         12      10mg\                    DON \> PLA: MMSE, CIBIC-plus\
  (Norway)\                                                                                                                              Inclusions: H-Y 4 ≧, age 45-- 95 years, MMSE 16--26\                                                                                                                                   dementia: DSM-IV                                             (crossover design)                                                                                        (flexible dose)          DON = PLA: UPDRS-motor, NPI
  Industry                                                                                                                               Exclusions: using anticholinergic drugs or psychotropic drugs with anticholinergic effects                                                                                                                                                                                                                                                                                             

                                                                                                                           PLA           12                                                                                                                                                                                                                                                                                                                                                                                     

  Beversdorf 2004\                                                                                                         7             Patients: DLB\                                                                                                                                                                         DLB: consensus diagnostic criteria                           4 weeks\                     65±3.47                42.9               NR             DON\        7       5 mg                     DON \> PLA: MMSE, ADAS-cog\
  (USA)\                                                                                                                                 Inclusions: NR\                                                                                                                                                                                                                                     (double crossover design)                                                             PLA                                          DON = PLA: BNT, HVLT, VSB, PSMS, IADL, UPDRS
  Industry                                                                                                                               Exclusions: NR                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                           7                                                                                                                                                                                                                                                                                                                                                                                                    

  Chung 2010\                                                                                                              23            Patients: PD\                                                                                                                                                                          Probable idiopathic PD: clinical diagnosis                   6 weeks (crossover design)   68.3±10.8              65.2               NR             DON         19      10mg.\                   DON \> PLA: fall frequency (falls/day)\
  (USA)\                                                                                                                                 Inclusions: a baseline frequency of falling or nearly falling 2 or more times per week\                                                                                                                                                                                                                                                                       (flexible dose)          DON = PLA: near-fall frequency (near falls/day), CGI-I, ABC, BB, UPDRS-motor, MMSE
  Industry                                                                                                                               Exclusions: H-Y = V, MMSE \< 25, using ChEI or anticholinergic or sedative-hypnotic properties                                                                                                                                                                                                                                                                                         

                                                                                                                           PLA           19                                                                                                                                                                                                                                                                                                                                                                                     

  Devos 2014\                                                                                                              30            Patients: PD\                                                                                                                                                                          PD: Gibb's criteria                                          6 months                     RIV: 68\               RIV: 69\           NR             RIV patch   16      9.5mg\                   RIV \> PLA: LARS, ZBI, IADL\
  (France)\                                                                                                                              Inclusions: LARS ≧ 16\                                                                                                                                                                                                                                                           PLA: 65\               PLA: 57                                               (flexible dose)          RIV = PLA: PDQ-39, MDRS, UPDRS-motor
  Non-industry                                                                                                                           Exclusions: dementia (MDS criteria), axis I psychiatric disorders (DSM-IVTR), MADRAS \> 18, DBS for less than 2 years, using cholinomimetic drugs or carbamate derivatives, age ≧ 80                                                                                             (median)                                                                                              

                                                                                                                           PLA           14                                                                                                                                                                                                                                                                                                                                                                                     

  Dubois 2012\                                                                                                             550           Patients: PDD\                                                                                                                                                                         PD: QSBBC\                                                   24 weeks                     DON 10 mg:\            DON 10 mg: 75\     DON 10 mg:\    DON 10 mg   182     10mg\                    DON 10mg \> PLA: CIBIC-plus, MMSE, VF (category), VF (letter), VF (switching), BTA\
  (Germany, Austria, Spain, Russia, UK, France, Australia, New Zealand, South Africa, Canada, Italy, Belgium, Portugal)\                 Inclusions: age ≧ 40 years, H-Y II-IV, MMSE 10--26\                                                                                                                                    dementia: DSM-IV                                                                          70.8±7.46\             DON 5 mg: 65\      White 98\                          (fixed dose)             DON 10mg = PLA: ADAS-cog, DAD, NPI, SE\
  Industry                                                                                                                               Exclusions: DLB (use consensus diagnostic criteria), previously treated with centrally ChEI, hypersensitivity PIP, using anticholinergics and cholinergic agents                                                                                                                 DON 5 mg:\             PLA: 65            Black 1\                                                    DON 5mg \> PLA: MMSE, VF (category), VF (letter), VF (switching), BTA\
                                                                                                                                                                                                                                                                                                                                                                                                                          72.0±6.83\                                Other 0.5\                                                  DON 5mg = PLA: ADAS-cog, CIBIC-plus, DAD, NPI, SE
                                                                                                                                                                                                                                                                                                                                                                                                                          PLA: 72.9±6.48                            DON 5 mg:\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    White 99\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Black 0\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Other 1\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PLA:\                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    White 100\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Black 0\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Other 0                                                     

  DON 5 mg                                                                                                                 195           5mg\                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                         (fixed dose)                                                                                                                                                                                                                                                                                                                                                                           

  PLA                                                                                                                      173           PLA                                                                                                                                                                                                                                                                                                                                                                                    

  Emre 2004\                                                                                                               541           Patients: PDD\                                                                                                                                                                         PD: UKPDSBB\                                                 24 weeks                     RIV: 72.8±6.7\         RIV: 64.6\         RIV:\          RIV         362     12mg\                    RIV \> PLA: ADAS-cog, ADCS-CGIC, ADCS-ADL, NPI-10, MMSE, CDRCAS, VF, CDT\
  (Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Norway, Portugal, Spain, Turkey, and UK)\                              Inclusions: age ≧ 50 years, MMSE 10--24, the onset of symptoms occurring at least two years after the diagnosis of PD\                                                                 dementia: DSM-IV                                                                          PLA: 72.4±6.4          PLA: 65.4          White 99.4\                        (flexible dose)          RIV = PLA: UPDRS-motor
  Industry                                                                                                                               Exclusions: hypersensitivity RIV or similar drugs, using ChEI or anticholinergic drugs                                                                                                                                                                                                                                     Other 0.6\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PLA:\                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    White 100\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Other 0                                                     

                                                                                                                           PLA           179                                                                                                                                                                                                                                                                                                                                                                                    

  Giacopo 2012\                                                                                                            12            Patients: PD\                                                                                                                                                                          PD: NR                                                       3 weeks\                     67.7±7.3               91.7               NR             RIV patch   10      4.6mg\                   RIV \> PLA: RBD episode frequency
  (Italy)\                                                                                                                               Inclusions: RBD, RBD phenomenon refractory to MEL and CLO\                                                                                                                                                                                          (crossover design)                                                                                        (fixed dose)             
  Non-industry                                                                                                                           Exclusions: dementia, using anticholinergics or antidepressants and DBS                                                                                                                                                                                                                                                                                                                

                                                                                                                           PLA           10                                                                                                                                                                                                                                                                                                                                                                                     

  Grace 2009\                                                                                                              69            Patients: PD\                                                                                                                                                                          PD: UKPDSBB                                                  16 weeks                     GAL: 65.9±9.6\         GAL: 78.9\         NR             GLA         38      24mg\                    GLA = PLA: CPT, COWA, 3MS, HVLT, TMT-A, TMT-B, OSDM, CDT, CWT, Clarity of thinking (VAS), PDQ-39, FrSBE, CB, NPI-Q, UPDRS-motor
  (USA)\                                                                                                                                 Inclusions: age 40--90 years, at least 6 years of formal education\                                                                                                                                                                                                              PLA: 68.8±10.0         PLA: 67.7                                             (fixed dose)             
  Non-industry                                                                                                                           Exclusions: dementia (DSM- IV), 3MS \< 77, GDS \> 7, using antipsychotic or anticholinergic medication                                                                                                                                                                                                                                                                                 

                                                                                                                           PLA           31                                                                                                                                                                                                                                                                                                                                                                                     

  Ikeda 2015\                                                                                                              142           Patients: DLB\                                                                                                                                                                         probable DLB: the consensus diagnostic criteria              12 weeks                     DON 10 mg: 77.7±6.8\   DON 10 mg: 42.9\   Japanese 100   DON 10 mg   49      10mg\                    DON 10mg \> PLA: MMSE\
  (Japan)\                                                                                                                               Inclusions: age ≧ 50 years, MMSE 10--26, CDR ≧ 0.5, NPI-plus ≧ 8 and NPI-2 ≧ 1\                                                                                                                                                                                                  DON 5 mg: 78.8±5.1\    DON 5 mg: 44.4\                                       (fixed dose)             DON 10mg = PLA: NPI-10, NPI-2, ZBI, UPDRS-motor\
  Industry                                                                                                                               Exclusions: hypersensitivity to DON or PIP derivatives, H-Y ≧ IV, treatment with ChEIs or any investigational drug within 3 months prior to screening                                                                                                                            PLA: 77.2±6.1          PLA: 38.6                                                                      DON 5mg = PLA: MMSE, NPI-10, NPI-2, ZBI, UPDRS-motor

                                                                                                                           DON 5 mg      47                                                                                                                                                                                     5mg\                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                (fixed dose)                                                                                                                                                                                    

                                                                                                                           PLA           46                                                                                                                                                                                                                                                                                                                                                                                     

  Leroi 2004\                                                                                                              16            Patients: PDD or CIPD\                                                                                                                                                                 PD: UKPDSBB\                                                 18 weeks                     DON: 66.2±9.3\         DON: 85.7\         NR             DON         7       10mg\                    DON \> PLA: MDRS memory subscore\
  (USA)\                                                                                                                                 Inclusions: on stable regimens of antiparkinsonian medication\                                                                                                                         dementia or cognitive impairment: DSM-IV                                                  PLA: 70.8±11.8         PLA: 44.4                                             (flexible dose)          DON = PLA: MMSE, MDRS, MDRS attention, MDRS initiation-perseveration, MDRS conceptual planning, MDRS construction, BTA, TMT-A, TMT-B, VF (sum of FAS), VF (category), HVLT-R total, HVLT-R recall, HVLT-R recognition, VMI, NPI, CSDD, UPDRS-ADL, UPDRS-motor, UPDRS-complication of treatment, H-Y
  Industry                                                                                                                               Exclusions: MMSE \< 10, known inability to tolerate DON                                                                                                                                                                                                                                                                                                                                

                                                                                                                           PLA           9                                                                                                                                                                                                                                                                                                                                                                                      

  Litvinenko 2008\                                                                                                         41            Patients: PDD\                                                                                                                                                                         PD: UKPDSBB\                                                 24 weeks                     GAL: 68.6±9.3\         NR                 NR             GAL         21      16 mg                    GLA \> PLA: MMSE, ADAS-cog, FAB, CDT, DAD\
  (Russia)\                                                                                                                              Inclusions: MMSE \< 25, presence of dementia developing two years from onset of PD\                                                                                                    dementia: ICD-10                                                                          UC: 72.6±8.6                                                                                          GLA = PLA: UPDRS-motor
  Non-industry                                                                                                                           Exclusions: using ChEI or nootropes, HAM-D \> 18                                                                                                                                                                                                                                                                                                                                       

                                                                                                                           UC            20                                                                                                                                                                                                                                                                                                                                                                                     

  Mamikonyan 2015\                                                                                                         28            Patients: CIPD\                                                                                                                                                                        PD: NR\                                                      10 weeks\                    64.3±8.2               78.6               White: 96.4    RIV patch   27      9.5mg\                   RIV \> PLA: ECB\
  (USA)\                                                                                                                                 Inclusions: age 40--85, CDR = 0.5, DRS-2 \< 8,\                                                                                                                                        MCI: Winblad criteria                                        (crossover design)                                                                                        (flexible dose)          RIV = PLA: ADCS-CGIC, MoCa, DRS-2, NCTS, GDS attention, State anxiety subscale of STAI, UPDRS-motor, GDS-15, PPRS, PDQ-8, PDAQ
  Industry                                                                                                                               Exclusions: PDD and DLB,                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                           PLA           27                                                                                                                                                                                                                                                                                                                                                                                     

  McKeith 2000\                                                                                                            120           Patients: DLB\                                                                                                                                                                         probable DLB: clinical diagnosis                             20 weeks                     RIV: 73.9±6.5\         RIV: 52.5\         NR             RIV         59      12mg\                    RIV \> PLA: NPI-4, NPI-10.\
  (Spain, UK and Italy)\                                                                                                                 Inclusions: MMSE ≧ 9\                                                                                                                                                                                                                                                            PLA: 73.9±6.4          PLA: 60.7                                             (flexible dose)          RIV = PLA: CGC-plus, MMSE
  Industry                                                                                                                               Exclusions: H-Y \> 3, UPDRS subscore \> 3, using neuroleptics, anticholinergics, SEL, or similar drugs                                                                                                                                                                                                                                                                                 

                                                                                                                           PLA           61                                                                                                                                                                                                                                                                                                                                                                                     

  Study                                                                                                                    Total n       Patients                                                                                                                                                                               Diagnosis                                                    Duration                     Age (mean+/-SD)        Male, %            Race (%)       Drug        n       Dose (dose mg/day)       Outcomes

  Mentis 2006\                                                                                                             18            Patients: PD\                                                                                                                                                                          PD: NR                                                       8 weeks                      NR                     DON: 80\           NR             DON         11      10mg\                    DON = LA: Outward movement, Out-and-back movement, Onset time, Timing error, Directional error.
  (USA)\                                                                                                                                 Inclusions: MMSE \>27, improve UPDRS 20% \< on motor medication\                                                                                                                                                                                                                                        PLA: 25                                               (fixed dose)             
  Industry                                                                                                                               Exclusions: taking anticholinergics, dementia                                                                                                                                                                                                                                                                                                                                          

                                                                                                                           PLA           7                                                                                                                                                                                                                                                                                                                                                                                      

  Mori 2012\                                                                                                               140           Patients: DLB\                                                                                                                                                                         probable DLB: the consensus diagnostic criteria              12 weeks                     DON 10 mg: 78.6±6.1\   DON 10 mg: 11.1\   Japanese 100   DON 10 mg   37      10mg\                    DON 10mg \> PLA: MMSE, WMS-R a/c, WAIS-III (symbol digit modalities subscale), NPI-10, NPI-4, NPI-2, ZBI, CIBIC-plus\
  (Japan)\                                                                                                                               Inclusions: age ≧ 50 years, MMSE 10--26, CDR ≧ 0.5, NPI-plus ≧ 8\                                                                                                                                                                                                                DON 5 mg: 77.9±6.8\    DON 5 mg: 50.0\                                       (fixed dose)             DON 10mg = PLA: VF (category), VF (letter), VPTA (form recognition), UPDRS-motor\
  Industry                                                                                                                               Exclusions: H-Y ≧ IV, treatment with ChEI or any investigational drug within 3 months prior to screening                                                                                                                                                                         DON 3 mg: 79.6±4.5\    DON 3 mg: 48.6\                                                                DON 5mg \> PLA: MMSE, WMS-R a/c, VF (category), VF (letter), WAIS-III (symbol digit modalities subscale), NPI-10, NPI-4, NPI-2, CIBIC-plus\
                                                                                                                                                                                                                                                                                                                                                                                                                          PLA: 78.6±4.7          PLA: 28.1                                                                      DON 5mg = PLA: VPTA (form recognition), ZBI, UPDRS-motor\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                DON 3mg \> PLA: MMSE, WAIS-III (symbol digit modalities subscale), NPI-2, CIBIC-plus\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                DON 3mg = PLA: WMS-R a/c, VF (category), VF (letter), VPTA (form recognition), NPI-10, NPI-4, ZBI, UPDRS-motor

                                                                                                                           DON 5 mg      33                                                                                                                                                                                     5mg\                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                (fixed dose)                                                                                                                                                                                    

                                                                                                                           DON 3 mg      35                                                                                                                                                                                     3mg\                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                (fixed dose)                                                                                                                                                                                    

                                                                                                                           PLA           35                                                                                                                                                                                     PLA                                                                                                                                                                                             

  Okereke 2004\                                                                                                            25            Patients: PD\                                                                                                                                                                          PD: NR                                                       15 days\                     74.0±1.9               NR                 NR             DON         23      5mg\                     DON = PLA: UPDRS-motor
  (USA)\                                                                                                                                 Inclusions: taking stable doses of L-dopa, patients were to weigh within 20% of their ideal weight\                                                                                                                                                 (crossover design)                                                                                        (fixed dose)             
  Industry                                                                                                                               Exclusions: use prohibited agent                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                           PLA           23                                                                                                                                                                                                                                                                                                                                                                                     

  Ravina 2005\                                                                                                             22            Patients: PDD\                                                                                                                                                                         PD: clinical diagnosis\                                      10 weeks\                    DON/PLA: 75.0±9.8\     DON/PLA: 100\      NR             DON         19      10mg\                    DON \> PLA: MMSE, CGI-C\
  (USA)\                                                                                                                                 Inclusions: age ≧ 40 years, MMSE 17--26\                                                                                                                                               dementia: DSM-IV                                             (crossover design)           PLA/DON: 72.1±8.1      PLA/DON: 60                                           (flexible dose)          DON = PLA: ADAS-cog, MDRS, BPRS, UPDRS total, UPDRS-motor
  Non-industry                                                                                                                           Exclusions: DLB, using cholinergic or anticholinergic agents except AMA or TOL within the 2 weeks prior to screening                                                                                                                                                                                                                                                                   

                                                                                                                           PLA           19                                                                                                                                                                                                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABC: Activities of Balance Confidence, ADAS-cog: Alzheimer's Disease Assessment Scale cognitive subscale, ADCS-ADL: Alzheimer's Disease Cooperative Study--Activities of Daily Living, ADCS-CGIC: Alzheimer's Disease Cooperative Study--Clinician's Global Impression of Change, ADL: activities of daily living, AMA: amantadine, BB: Berg Balance, BNT: Boston Naming Test, BPRS: Brief Psychosis Rating Scale, BTA: Brief test of Attention, CB: informant-based Cornell-Brown scale for quality of life in dementia, CDR: Clinical Dementia Rating, CDRCAS: Cognitive Drug Research Computerized Assessment System, CDT: clock drawing test, CGC-plus: Clinical Global Change-plus, CGI-C: Clinical Global Impression of change, CGI-I: Clinical Global Impression - Improvement scale, ChEI: cholinesterase inhibitor, CIBIC-plus: Clinician's Interview-Based Impression of Change Plus Caregiver Input, CIPD: cognitive impairment in Parkinson's disease, CLO: clonazepam, COWA: Controlled Oral Word Association, CPT: Conners Continuous Performance Test, CSDD: Cornell Scale for Depression in Dementia, CT: computed tomography, CWT: Color-Word Test, DAD: Disability Assessment for Dementia, DBS: deep brain stimulation, DLB: Dementia with Lewy bodies, DON: donepezil, DRS-2: Dementia Rating Scale-2, DSM-IV (TR): Diagnostic and Statistical Manual of Mental Disorders-4th edition (Text Revision), ECB: Everyday Cognition Battery, FAB: Frontal Assessment Battery, FrSBe: Frontal Systems Behavior Scale, GAL: galantamine, GDS: Gordon Diagnostic System, GDS-SF: Geriatric Depression Scale-Short Form, GDS-15: Geriatric Depression Scale-15, HAM-D: Hamilton Rating Scale for Depression, HVLT(-R): Hopkins Verbal Learning Test(-Revised), H-Y: Hoehn and Yahr scale, IADL: Instrumental Activities of Daily Living, ICD: International Classification of Diseases, LARS: the sensitive Lille Apathy Rating Scale, MADRS: Montgomery--Asberg Depression Rating Scale, MDS: the Movement Disorders Society, MDRS: Mattis Dementia Rating Scale, MEL: melatonin, MMSE: Mini-Mental State Examination, MoCa: Montreal Cognitive Assessment, NCTS: Neurotrax Comprehensive Testing Suite, NPI: neuro-psychiatric inventory, NR: Not report, OSDM: Symbol Digit Modalitied Test, PD: Parkinson's disease, PDAQ: Penn Daily Activities Questionnaire, PDD: Parkinson's disease dementia, PDQ-8: Parkinson's Disease Questionnaire-8, PDQ-39: Parkinson's Disease Questionnaire-39, PPRS: Parkinson Psychosis Rating Scale, PIP: piperidine, PLA: placebo, PSMS: Physical Self-Maintenance Scale, QSBBC: Queen Square Brain Bank Criteria, RBD: rapid eye movement behavior disorder, RIV: rivastigmine, SD: standard deviation, SE: Schwab and England, SEL: selegiline, STAI: State Trait Anxiety Inventory, TMT: Trail Making Test, TOL: tolterodine, UC: usual care, UKPDSBB: the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria, UPDRS: unified Parkinson's disease rating scale, VAS: Visual Analogue Scale, VF: Verbal Fluency, VMI: develop-mental test of Visual-Motor Integration, VPTA: Visual Perception Test for Agnosia, VSB: Verbal Learning Test, WAIS-Ⅲ: Wechsler Adult Intelligence Scale, WMS-R a/c: Wechsler Memory Scale-Revised attention/concentration subscale, ZBI: Zarit Burden Interview, 3MS: Modified Mini-Mental Status Exam

![Risk of bias assessment.](ijnppy_pyv086_f0002){#F2}

Meta-Analysis for Primary Outcomes {#s7}
----------------------------------

### Cognitive Function {#s8}

Pooled ChEIs improved cognitive function scores compared with control treatments (SMD = −0.53, 95% CI = −0.72 to −0.35, *P*\<.0001, *I* ^2^=68%, 16 comparisons, n=1889) ([Figure 3](#F3){ref-type="fig"}). Visual inspection of the funnel plots for primary outcomes did not suggest the presence of publication bias ([Figure 4a](#F4){ref-type="fig"}). For individual ChEIs, donepezil and rivastigmine significantly improved cognitive function scores compared with placebo (donepezil: SMD=−0.51, 95% CI=−0.69 to −0.34, *P*\<.00001, *I* ^2^=41%, 11 comparisons, n=1148 and rivastigmine: SMD=−0.29, 95% CI=−0.45 to −0.13, *P*=.0004, *I* ^2^=0%, 3 comparisons, n=648). In contrast, there was no significant difference in cognitive function scores between galantamine and control groups (SMD=−1.5, 95% CI=−3.62 to 0.62, *P*=.17, *I* ^2^=94%, 2 comparisons, n=93).

![Forest plot of cognitive function (16 comparisons, n = 1889).](ijnppy_pyv086_f0003){#F3}

![Funnel plots. (a) Cognitive function. (b) Behavioral disturbance. (c) Motor function.](ijnppy_pyv086_f0004){#F4}

### Sensitivity Analyses of Cognitive Function {#s9}

There was significant heterogeneity in cognitive function scores among the studies (*I* ^*2*^=68%) ([Figure 3](#F3){ref-type="fig"}). Therefore, we performed several sensitivity analyses for identifying confounding factors affecting cognitive function scores ([Table 2a](#T2a){ref-type="table"}). When divided into a double-blind RCT subgroup and "other" subgroup, the significant heterogeneity disappeared in the double-blind RCT subgroup (double-blind RCTs subgroup \[n=15\], *I* ^2^=39%; other subgroup \[n=1 galantamine study ([@CIT0025])\], *I* ^2^=not applicable (NA); test for subgroup differences, *I* ^2^=95.6%, *P\<*.00001\]. When divided into placebo-controlled and non-placebo--controlled trial subgroups, the same results were found. When divided according to the tested ChEIs, the significant heterogeneity disappeared in donepezil and rivastigmine subgroups (donepezil subgroup: *I* ^2^=41%; rivastigmine subgroup: *I* ^2^=0%); however, heterogeneity remained in the galantamine subgroup (*I* ^2^=94%). When divided into DLB, PDD + CIPD, and PD subgroups, there was significant heterogeneity among all subgroups (DLB: *I* ^2^=56%; PDD+CIPD: *I* ^2^=76%; PD: *I* ^2^=61%). ChEIs significantly affected cognitive function scores for DLB and PDD+CIPD subgroups (DLB: SMD=−0.58, 95% CI=−0.86 to −0.31, *P\<*.0001, *I* ^2^=56%, 6 comparisons, n=496 and PDD+CIPD: SMD=−0.59; 95% CI=−0.88 to −0.30, *P\<*.0001, *I* ^2^=76%, 8 comparisons, n=1301). In contrast, there was no effect of ChEIs on cognitive function scores in the PD subgroup (SMD=−0.12, 95% CI=−0.79 to 0.54, *P*=.72, *I* ^2^=61%, 2 comparisons, n=92). When divided into long duration (\>12 weeks) and short duration (≤12 weeks) subgroups, there was significant heterogeneity in both subgroups (long duration subgroup: *I* ^2^=80%; short duration subgroup: *I* ^2^=55%). When divided into high-quality trial (double-blind, randomized, parallel, placebo-controlled trial as well as ITT or modified ITT analysis) and "other" subgroups, the significant heterogeneity disappeared in the high-quality trials subgroup (*I* ^2^=45%) but remained in the "other" subgroup (*I* ^2^=85). Further, when divided into large and small sample size subgroups, the significant heterogeneity disappeared in the small sample size subgroup (*I* ^2^=7%) but remained in the large sample size subgroup (*I* ^2^=75%). When divided into industry and nonindustry subgroups, the significant heterogeneity disappeared in the industry subgroup (*I* ^2^=48%) but remained in the nonindustry subgroup (*I* ^2^=89%).

###### 

Sensitivity Analysis of Efficacy of Cholinesterase Inhibitors (Cognitive Function)

  Variable                        Subgroup                           N      n      I^2^    SMD              95% CI           P value          Test for Subgroup Differences
  ------------------------------- ---------------------------------- ------ ------ ------- ---------------- ---------------- ---------------- ---------------------------------
  Blinding                        Double blind                       15     1850   39      -0.46            -0.60 to -0.32   **\< 0.00001**   I^2^ = 95.6 %, **P \< 0.00001**
  Others                          1                                  39     NA     -2.61   -3.49 to -1.73   **\< 0.00001**                    
  Cholinesterase inhibitor        Donepezil                          11     1148   41      -0.51            -0.69 to -0.34   **\< 0.00001**   I^2^ = 54.3 %, P = 0.11
  Galantamine                     2                                  93     94     -1.5    -3.62 to 0.62    0.17                              
  Rivastigmine                    3                                  648    0      -0.29   -0.45 to -0.13   **0.0004**                        
  Control                         Placebo                            15     1850   39      -0.46            -0.60 to -0.32   **\< 0.00001**   I^2^ = 95.6 %, **P \< 0.00001**
  Non-placebo                     1                                  39     NA     -2.61   -3.49 to -1.73   **\< 0.00001**                    
  Diagnosis                       DLB                                6      496    56      -0.58            -0.86 to -0.31   **\< 0.0001**    I^2^ = 0 %, P = 0.43
  PDD + CIPD                      8                                  1301   76     -0.59   -0.88 to -0.30   **\< 0.0001**                     
  PD                              2                                  92     61     -0.12   -0.79 to 0.54    0.72                              
  Duration                        \<12 weeks                         8      1413   80      -0.55            -0.82 to -0.28   **\< 0.0001**    I^2^ = 0 %, P = 0.91
  ≥12 weeks                       8                                  476    55     -0.53   -0.81 to -0.24   **0.0003**                        
  Quality of the trial design\*   High-quality trials trial design   11     1723   45      -0.48            -0.63 to -0.34   **\< 0.00001**   I^2^ = 0 %, P = 0.55
  Others                          5                                  166    85     -0.75   -1.62 to 0.11    0.09                              
  Sample size                     Total n \> 28                      11     1744   75      -0.61            -0.83 to -0.39   **\< 0.00001**   I^2^ = 67.2 %, P = 0.08
  Total n ≤ 28                    5                                  143    7      -0.25   -0.59 to 0.10    0.17                              
  Sponsorship                     Industry                           13     1758   48      -0.46            -0.62 to -0.31   **\< 0.00001**   I^2^ = 16.9%, P = 0.27
  Non-industry                    3                                  131    89     -1.14   -2.33 to 0.06    0.06                              

CI, confidence interval; CIPD, cognitive impairment in Parkinson's disease; DLB, Dementia with Lewy bodies; NA, not applicable; PD, Parkinson's disease; PDD, Parkinson's disease dementia; SMD, standardized mean difference.

\*High-quality trials trial design: double-blind, parallel, randomized, placebo-controlled trial, intention to treat population or modified intention to treat population,

Others: crossover trial, non-placebo--controlled trial, nonintention to treat population trial.

###### 

Sensitivity Analysis of Efficacy of Cholinesterase Inhibitors (Behavioral Disturbance)

  Variable                        Subgroup                           N      n      I^2^    SMD              95% CI           P value     Test for subgroup differences
  ------------------------------- ---------------------------------- ------ ------ ------- ---------------- ---------------- ----------- ---------------------------------
  Blinding                        Double blind                       12     1793   14      -0.17            -0.27 to -0.06   **0.003**   I^2^ = 98.0 %, **P \< 0.00001**
  Others                          1                                  39     NA     -5.02   -6.36 to -3.69   **\< 0.00001**               
  Cholinesterase inhibitor        Donepezil                          9      1130   36      -0.14            -0.31 to 0.02    0.09        I^2^ = 0 %, P = 0.55
  Galantamine                     2                                  82     98     -2.52   -7.35 to 2.31    0.31                         
  Rivastigmine                    2                                  620    0      -0.21   -0.37 to -0.04   **0.01**                     
  Control                         Placebo                            12     1793   14      -0.17            -0.27 to -0.06   **0.003**   I^2^ = 98.0 %, **P \< 0.00001**
  Non-placebo                     1                                  39     NA     -5.02   -6.36 to -3.69   **\< 0.00001**               
  Diagnosis                       DLB                                6      500    58      -0.13            -0.40 to 0.14    0.35        I^2^ = 24.2 %, P = 0.27
  PDD + CIPD                      6                                  1289   90     -0.54   -0.98 to -0.10   **0.02**                     
  PD                              1                                  43     NA     -0.09   -0.70 to 0.51    0.76                         
  Duration                        12 weeks \<                        7      1414   88      -0.47            -0.84 to -0.10   **0.01**    I^2^ = 58.9 %, P = 0.12
  12 weeks ≧                      6                                  418    55     -0.1    -0.39 to 0.20    0.52                         
  Quality of the trial design\*   High-quality trials trial design   11     1755   21      -0.17            -0.28 to -0.05   **0.005**   I^2^ = 0 %, P = 0.35
  Others                          2                                  77     98     -2.49   -7.38 to 2.40    0.32                         
  Sample size                     Total n \> 28                      11     1778   84      -0.3             -0.57 to -0.04   **0.03**    I^2^ = 0 %, P = 0.52
  Total n ≦ 28                    2                                  54     0      -0.11   -0.65 to 0.43    0.69                         
  Sponsorship                     Industry                           10     1712   28      -0.17            -0.29 to -0.04   **0.008**   I^2^ = 39.6%, P = 0.20
  Non-industry                    3                                  120    96     -1.62   -3.82 to 0.58    0.15                         

CI, confidence interval; CIPD, cognitive impairment in Parkinson's disease; DLB, Dementia with Lewy bodies; NA, not applicable; PD, Parkinson's disease; PDD, Parkinson's disease dementia; SMD, standardized mean difference.

\*High-quality trials trial design: double-blind, parallel, randomized, placebo-controlled trial, intention to treat population or modified intention to treat population,

Others: crossover trial, non-placebo--controlled trial, nonintention to treat population trial.

### Behavioral Disturbance {#s10}

Pooled ChEIs improved behavioral disturbance scores compared with control treatments (SMD=−0.28, 95% CI=−0.53 to −0.03, *P*=.03, *I* ^2^=81%, 13 comparisons, n=1832) ([Figure 5](#F5){ref-type="fig"}). Visual inspection of the funnel plots for primary outcomes did not suggest the presence of publication bias ([Figure 4b](#F4){ref-type="fig"}). For individual ChEIs, rivastigmine was significantly more efficacious than placebo (SMD=−0.21, 95% CI=−0.37 to −0.04, *P*=.01, *I* ^2^=0%, 2 comparisons, n=620). There was also a trend toward improved behavioral disturbance scores for donepezil compared with that for placebo (SMD=−0.14, 95% CI=−0.31 to 0.02, *P*=.09, *I* ^2^=36%, 9 comparisons, n=1130), while galantamine had no significant effect compared with control treatment (SMD=−2.52, 95% CI=−7.35 to 2.31, *P*=.31; *I* ^2^=98%, 2 comparisons, n=82).

![Forest plot of behavioral disturbance (13 comparisons, n = 1832).](ijnppy_pyv086_f0005){#F5}

### Sensitivity Analyses of Behavioral Disturbance {#s11}

There was significant heterogeneity in behavioral disturbance scores among the studies (*I* ^*2*^=81%) ([Figure 5](#F5){ref-type="fig"}). Therefore, we performed several sensitivity analyses for identifying confounding factors affecting behavioral disturbance scores ([Table 2b](#T2b){ref-type="table"}). When divided into a double-blind RCT subgroup and "other" subgroup, the significant heterogeneity disappeared in the double-blind RCT subgroup (double-blind RCTs subgroup \[n=12\], *I* ^2^=14%; other subgroup \[n=1 galantamine study ([@CIT0025])), *I* ^2^=NA; test for subgroup differences, *I* ^2^=98.0%, *P\<*.00001\]. When divided into placebo-controlled and non-placebo--controlled trial subgroups, the same results were found. When divided according to the tested ChEIs, the significant heterogeneity disappeared in the donepezil and rivastigmine subgroups (donepezil subgroup: *I* ^2^=36%; rivastigmine subgroup: *I* ^2^=0%); however, heterogeneity remained in the galantamine subgroup (*I* ^2^=98%). When divided into DLB, PDD+CIPD, and PD subgroups, there was significant heterogeneity in the DLB and PDD+CIPD subgroups (DLB: *I* ^2^=58%; PDD+CIPD: *I* ^2^=90%). ChEIs significantly affected behavioral disturbance scores for PDD+CIPD subgroups (SMD=−0.54; 95% CI=−0.98 to −0.10, *P*=.02, *I* ^2^=90%, 6 comparisons, n=1289). In contrast, there was no effect of ChEIs on behavioral disturbance scores in the DLB subgroup (SMD=−0.13, 95% CI=−0.40 to 0.14, *P*=.35, *I* ^2^=58%, 6 comparisons, n=500). We did not perform meta-analysis on behavioral disturbance scores for PD subgroup, because there was only one relevant study ([@CIT0019]). This study revealed that no significant differences in behavioral disturbance scores were found between groups (SMD=−0.09, 95% CI=−0.70 to 0.51, *P*=.76, *I* ^2^=NA, n=43). When divided into long duration and short duration subgroups, there was significant heterogeneity in both subgroups (long duration subgroup: *I* ^2^=88%; short duration subgroup: *I* ^2^=55%). ChEIs significantly affected behavioral disturbance scores for long duration subgroups (SMD=−0.47; 95% CI=−0.84 to −0.10, *P*=.01, *I* ^2^=88%, 7 comparisons, n=1414). In contrast, there was no effect of ChEIs on behavioral disturbance scores in the short duration subgroups (SMD=−0.1, 95% CI=−0.39 to 0.20, *P*=.52, *I* ^2^=55%, 6 comparisons, n=418). When divided into high-quality trial and other subgroups, the significant heterogeneity disappeared in the high-quality trials subgroup (*I* ^2^=21%) but remained in the "other" subgroup (*I* ^2^=98). ChEIs significantly affected behavioral disturbance scores for high-quality trial subgroups (SMD=−0.17; 95% CI=−0.28 to −0.05, *P*=.005, *I* ^2^=21%, 11 comparisons, n=1755). In contrast, there was no effect of ChEIs on behavioral disturbance scores in the other subgroups (SMD=−2.49, 95% CI=−7.38 to 2.40, *P*=.32, *I* ^2^=98%, 2 comparisons, n=77). Further, when divided into large and small sample size subgroups, the significant heterogeneity disappeared in the small sample size subgroup (*I* ^2^=0%) but remained in the large sample size subgroup (*I* ^2^=84%). ChEIs significantly affected behavioral disturbance scores for large sample size subgroup (SMD=−0.3; 95% CI=−0.57 to −0.04, *P*=.03, *I* ^2^=84%, 11 comparisons, n=1778). In contrast, there was no effect of ChEIs on behavioral disturbance scores in the small sample size subgroup (SMD=−0.11, 95% CI=−0.65 to 0.43, *P*=.69, *I* ^2^=0%, 2 comparisons, n=54). When divided into industry and nonindustry subgroups, the significant heterogeneity disappeared in the industry subgroup (*I* ^2^=28%) but remained in the nonindustry subgroup (*I* ^2^=96%). ChEIs significantly affected behavioral disturbance scores for industry subgroup (SMD=−0.17; 95% CI=−0.29 to −0.04, *P*=.008, *I* ^2^=28%, 10 comparisons, n=1712). In contrast, there was no effect of ChEIs on behavioral disturbance scores in the nonindustry subgroup (SMD=−1.62, 95% CI=−3.82 to 0.58, *P*=.15, *I* ^2^=96%, 3 comparisons, n=120).

### Motor Function {#s12}

Changes in UPDRS-motor scores were not significantly different from control treatments (SMD=−0.02, 95% CI=−0.14 to 0.10, *P*=.76, *I* ^2^=8%, 15 comparisons, n=1312) ([Figure 6](#F6){ref-type="fig"}). Visual inspection of the funnel plots for primary outcomes did not suggest the presence of publication bias ([Figure 4c](#F4){ref-type="fig"}). For individual ChEIs (donepezil, galantamine, and rivastigmine), no significant differences in UPDRS-motor scores were found between groups.

![Forest plot of motor function (15 comparisons, n = 1312).](ijnppy_pyv086_f0006){#F6}

Meta-Analysis for Secondary Outcomes {#s13}
------------------------------------

### Activities of Daily Living {#s14}

Pooled ChEIs improved ADL scores compared with placebo (SMD=−0.28) ([Table 3](#T3){ref-type="table"}). For individual ChEIs, donepezil significantly improved ADL scores compared with placebo (SMD=−0.37). We could not perform a meta-analysis for rivastigmine, because there was only one study reporting ADL scores ([@CIT0014]); however, this study revealed that rivastigmine significantly improved ADL scores compared with placebo (SMD=−0.21).

###### 

Meta-Analysis of Secondary Outcomes of Cholinesterase Inhibitors

  Outcome                                      ChEI        N      n     I^2^    SMD              95% CI           P                              
  -------------------------------------------- ----------- ------ ----- ------- ---------------- ---------------- -------------- --------------- -----------
  Activities of daily living                   Donepezil   6      373   0       -0.37            -0.58 to -0.17   **0.0004**                     
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           498    NA    -0.21   -0.40 to -0.02   **0.003**                                       
  Pooled ChEIs                                 7           871    0     -0.28   -0.42 to -0.15   **\<0.0001**                                    
  Global function assessment                   Donepezil   8      968   71      -0.61            -0.89 to -0.33   **\<0.0001**                   
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 2           521    0     -0.34   -0.53 to -0.16   **0.0002**                                      
  Pooled ChEIs                                 10          1489   62    -0.52   -0.73 to -0.31   **\<0.00001**                                   
  Outcome                                      ChEI        N      n     I^2^    RR               95% CI           P for RR       NNH             P for NNH
  Discontinuation rate due to all causes       Donepezil   8      925   0       1.33             0.99 to 1.78     0.06                           
  Galantamine                                  2           110    65    1.04    0.09 to 12.57    0.98                                            
  Rivastigmine                                 5           731    0     1.59    1.16 to 2.17     **0.004**        NS                             
  Pooled ChEIs                                 15          1766   0     1.48    1.20 to 1.82     **0.0002**       14             0.02            
  Discontinuation rate due to adverse events   Donepezil   8      925   0       1.35             0.92 to 1.97     0.13                           
  Galantamine                                  2           110    NA    2.45    1.00 to 5.98     0.05                                            
  Rivastigmine                                 4           703    14    1.7     0.94 to 3.08     0.08                                            
  Pooled ChEIs                                 14          1738   0     1.59    1.20 to 2.10     **0.001**        20             0.04            
  At least one adverse events                  Donepezil   7      964   0       1.08             0.99 to 1.18     0.1                            
  Galantamine                                  1           69     NA    1.12    0.97 to 1.29     0.13                                            
  Rivastigmine                                 3           691    6     1.18    1.08 to 1.30     **0.0005**       9              0.04            
  Pooled ChEIs                                 11          1724   0     1.13    1.06 to 1.19     **\<0.0001**     11             0.0001          
  Severe adverse events                        Donepezil   3      831   32      0.97             0.45 to 2.10     0.95                           
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 2           150    0     1.16    0.51 to 2.66     0.72                                            
  Pooled ChEIs                                 5           981    0     1.21    0.83 to 1.76     0.31                                            
  Outcome                                      ChEI        N      n     I^2^    RR               95% CI           P for RR       NNH             P for NNH
  Diarrhea                                     Donepezil   5      806   19      1.2              0.55 to 2.60     0.65                           
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           541    NA    1.61    0.74 to 3.48     0.23                                            
  Pooled ChEIs                                 6           1347   3     1.34    0.81 to 2.24     0.26                                            
  Dizziness                                    Donepezil   4      768   32      1.27             0.77 to 2.10     0.35                           
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           541    NA    5.19    1.23 to 21.90    **0.02**         20             **0.001**       
  Pooled ChEIs                                 5           1309   66    1.81    0.85 to 3.85     0.12                                            
  Hallucination                                Donepezil   2      689   0       0.6              0.31 to 1.17     0.13                           
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 2           597    29    0.64    0.26 to 1.62     0.35                                            
  Pooled ChEIs                                 4           1286   0     0.58    0.37 to 0.91     **0.02**         NS                             
  Insomnia                                     Donepezil   3      626   60      1.33             0.22 to 8.00     0.76                           
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           56     NA    2       0.40 to 10.05    0.4                                             
  Pooled ChEIs                                 4           682    40    1.66    0.51 to 5.39     0.4                                             
  Nausea                                       Donepezil   6      948   0       2.39             1.46 to 3.90     **0.0005**     NS              
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           541    NA    2.6     1.67 to 4.04     **\<0.0001**     6              **\<0.00001**   
  Pooled ChEIs                                 7           1489   0     2.5     1.80 to 3.47     **\<0.00001**    13             **0.05**        
  Parkinson symptoms                           Donepezil   3      831   0       1.58             0.91to 2.75      0.11                           
  Galantamine                                  1           69     NA    1.36    0.80 to 2.32     0.26                                            
  Rivastigmine                                 1           30     NA    0.29    0.01 to 6.69     0.44                                            
  Pooled ChEIs                                 5           930    0     1.43    0.97 to 2.09     0.07                                            
  Outcome                                      ChEI        N      n     I^2^    RR               95% CI           P for RR       NNH             P for NNH
  Tremor                                       Donepezil   1      550   NA      2.48             0.97 to 6.33     0.06                           
  Galantamine                                  1           69     NA    2.04    0.71 to 5.88     0.19                                            
  Rivastigmine                                 2           597    0     2.33    1.18 to 4.58     **0.01**         17             **0.002**       
  Pooled ChEIs                                 4           1216   0     2.3     1.41 to 3.75     **0.0008**       20             **\<0.0001**    
  Vomiting                                     Donepezil   2      689   71      1.73             0.10 to 29.06    0.7                            
  Galantamine                                  0           0      NA    NA      NA               NA                                              
  Rivastigmine                                 1           541    NA    9.89    3.15 to 31.10    **\<0.0001**     7              **\<0.00001**   
  Pooled ChEIs                                 3           1230   61    4.09    0.90 to 18.67    0.07                                            

ChEI, cholinesterase inhibitor; CI, confidence interval; N, number of comparisons; n, number of patients; NA, not applicable; NNH, number needed to harm; NS, not significant; RR, risk ratio; SMD, standardized mean difference.

### Global Function Assessment {#s15}

Pooled ChEIs improved global function assessment scores compared with placebo (SMD=−0.52) ([Table 3](#T3){ref-type="table"}). For individual ChEIs, donepezil and rivastigmine significantly improved global function assessment scores compared with placebo (donepezil: SMD=−0.61 and rivastigmine: SMD=−0.34).

### Safety Outcomes {#s16}

There was a significantly higher all-cause discontinuation rate in the pooled ChEIs group compared with controls (RR=1.48, NNH=14) ([Table 3](#T3){ref-type="table"}). Rivastigmine was associated with higher all-cause discontinuation rate than placebo (RR=1.59, NNH was not significant).

There was a significantly higher discontinuation rate because of adverse events in the pooled ChEIs group compared with the control group (RR=1.59, NNH=20) ([Table 3](#T3){ref-type="table"}).

There was a significantly higher rate of at least one adverse event between pooled ChEIs and placebo groups (RR=1.13, NNH=11) ([Table 3](#T3){ref-type="table"}). For individual ChEIs, there was a significantly higher rate of at least one adverse event for rivastigmine compared with placebo (RR=1.18, NNH=9). For donepezil and galantamine, the rates of at least one adverse event were similar between groups. The incidence of severe adverse events was similar between pooled ChEIs and placebo groups. The rates of severe adverse events were similar between groups (there were no data for galantamine).

With respect to individual adverse events, the pooled ChEIs group treatment was associated with a lower incidence of hallucination than placebo group (RR=0.58, NNH was not significant) ([Table 3](#T3){ref-type="table"}). The pooled ChEIs group had a higher incidence of nausea than the placebo group (RR=2.50, NNH=13). For individual ChEIs, donepezil was associated with a higher incidence of nausea than placebo (RR=2.39, NNH was not significant). Rivastigmine was associated with a higher incidence of nausea than placebo (RR=2.60, NNH=6). The pooled ChEIs group had a higher incidence of tremor than the placebo group (RR=2.30, NNH=20). For individual ChEIs, rivastigmine was associated with a higher incidence of tremor than placebo (RR=2.33, NNH=17). No significant differences were found in the incidences of diarrhea, vomiting, PD symptoms, insomnia, and dizziness between pooled ChEIs and placebo groups. Rivastigmine was associated with a higher incidence of vomiting and dizziness than placebo (vomiting: RR=9.89, NNH=7; dizziness: RR=5.19, NNH=20).

Discussion {#s17}
==========

To our knowledge, this is the first comprehensive meta-analysis of RCTs assessing the efficacy and safety of ChEIs for Lewy body disorders. The main results indicate that ChEIs improve cognitive function, behavioral disturbances, ADL, and global function compared with placebo. Moreover, pooled ChEIs did not worsen motor function. According to the effect sizes of individual ChEIs for cognitive function, donepezil was the most effective (SMD=−0.51), followed by rivastigmine (SMD=−0.29), while galantamine had no significant effect compared with placebo. Further, only rivastigmine significantly improved behavioral disturbances compared with placebo; however, even these effects were small (SMD=−0.21). We suggest that the significant heterogeneity among studies of cognitive function and behavioral disturbances was because of variation in quality of the trial design, because the heterogeneity was reduced after excluding one open-label, non-placebo--controlled trial ([@CIT0025]). Sensitivity analysis also revealed heterogeneity because of blinding methods. One previous meta-analysis of DLB, PDD, and CIPD ([@CIT0041]) reported that ChEIs were superior to placebo in several efficacy outcomes (cognitive function, behavioral disturbances, ADL, global function, and motor function) similar to the results of our meta-analysis. Further, we found that ChEIs significantly improved cognitive function in the DLB and PDD + CIPD patient groups, but not in the PD group. These results are strongly suggesting considerations for approving ChEIs for Lewy Body disorders to treat cognitive decline. In addition, we found that ChEIs significantly improved behavioral disturbances in PDD+CIPD patient group, but not in the DLB and PD groups. Further, we found that ChEIs significantly improved ADL in patients with DLB and PDD+CIPD. Moreover, because number of studies of galantamine and rivastigmine were small, a multiple-network meta-analysis of all anti-dementia drugs including memantine will be required to increase a statistical power.

While these drugs were effective against several cardinal deficits associated with Lewy body diseases, there were also significantly higher rates of all-cause discontinuation, discontinuation because of adverse events, and incidence of at least one adverse event in the pooled ChEIs group compared with controls. Moreover, ChEI treatment was associated with a higher incidence of nausea and tremor compared with placebo. For individual ChEIs, rivastigmine was associated with a higher incidence of vomiting and dizziness compared with placebo.

These conclusions must be considered considering several limitations. The first limitation is that our meta-analysis includes "gray" studies supported by pharmaceutical companies. However, these represented the majority of the retrieved articles. Nonetheless, they appear in peer-reviewed journals. Moreover, there were no significant subgroup differences between industry-sponsored and non-industry--sponsored studies (*I* ^*2*^=39.6%, *P*=.20). The second limitation is that characteristics the studies included in the meta-analysis ([Table 1](#T1){ref-type="table"}). The third limitation is that included studies had several risk of bias ([Figure 2](#F2){ref-type="fig"}). The fourth limitation is that patients with dementia are known to have a poor drug compliance ([@CIT0003]), reducing the measured effectiveness. Finally, several studies included in this meta-analysis did not report any available data on symptom scales and safety outcomes; therefore, the outcome results for efficacy and safety did not include data from all the 17 studies.

In conclusion, ChEIs are beneficial for the treatment of Lewy body disorders as assessed by multiple scales evaluating cognition, behavioral disturbances, ADL, and global function. Moreover, ChEIs do not worsen motor function. However, a careful monitoring of treatment compliance and side effects is required.
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